"QuantityPath","Parameter","PKParameter","Value"
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Lipophilicity","C_max",-0.255031252831566
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Specific intestinal permeability (transcellular)","C_max",0.269424577038825
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A9-Kassahun 2007-In vitro Vmax for liver microsomes","C_max",-0.0877437108023988
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A1-Kassahun 2007-In vitro Vmax for liver microsomes","C_max",-0.262752845965788
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Iwamoto 2008 25mg PO (Figure 2) Safety-Tolerability-PK study-Weibull (lactose formulation)-Dissolution shape","C_max",0.721964903558603
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Lipophilicity","t_max",0
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Specific intestinal permeability (transcellular)","t_max",-0.166666666666667
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A9-Kassahun 2007-In vitro Vmax for liver microsomes","t_max",0
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A1-Kassahun 2007-In vitro Vmax for liver microsomes","t_max",0
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Iwamoto 2008 25mg PO (Figure 2) Safety-Tolerability-PK study-Weibull (lactose formulation)-Dissolution shape","t_max",0
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Lipophilicity","C_tEnd",-0.658359559744715
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Specific intestinal permeability (transcellular)","C_tEnd",-0.142655130484818
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A9-Kassahun 2007-In vitro Vmax for liver microsomes","C_tEnd",-0.464554554684922
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A1-Kassahun 2007-In vitro Vmax for liver microsomes","C_tEnd",-0.665733153290505
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Iwamoto 2008 25mg PO (Figure 2) Safety-Tolerability-PK study-Weibull (lactose formulation)-Dissolution shape","C_tEnd",0.241492879163546
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Lipophilicity","AUC_tEnd",-0.365958891769752
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Specific intestinal permeability (transcellular)","AUC_tEnd",0.142999852527115
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A9-Kassahun 2007-In vitro Vmax for liver microsomes","AUC_tEnd",-0.24861173284563
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A1-Kassahun 2007-In vitro Vmax for liver microsomes","AUC_tEnd",-0.454422472738296
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Iwamoto 2008 25mg PO (Figure 2) Safety-Tolerability-PK study-Weibull (lactose formulation)-Dissolution shape","AUC_tEnd",0.638913293882079
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Lipophilicity","AUC_inf",-0.400453192487532
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Specific intestinal permeability (transcellular)","AUC_inf",0.127403966922441
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A9-Kassahun 2007-In vitro Vmax for liver microsomes","AUC_inf",-0.254351596951368
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A1-Kassahun 2007-In vitro Vmax for liver microsomes","AUC_inf",-0.456297157244711
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Iwamoto 2008 25mg PO (Figure 2) Safety-Tolerability-PK study-Weibull (lactose formulation)-Dissolution shape","AUC_inf",0.597972570165805
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Lipophilicity","MRT",-0.246647356776809
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Specific intestinal permeability (transcellular)","MRT",-0.162693497647407
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A9-Kassahun 2007-In vitro Vmax for liver microsomes","MRT",-0.105029410083081
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A1-Kassahun 2007-In vitro Vmax for liver microsomes","MRT",-0.0932335406419585
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Iwamoto 2008 25mg PO (Figure 2) Safety-Tolerability-PK study-Weibull (lactose formulation)-Dissolution shape","MRT",-0.297649994786964
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Lipophilicity","Thalf",-0.359379222423442
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Specific intestinal permeability (transcellular)","Thalf",-0.00874533218219832
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A9-Kassahun 2007-In vitro Vmax for liver microsomes","Thalf",0.107554684397033
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A1-Kassahun 2007-In vitro Vmax for liver microsomes","Thalf",0.175590006226233
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Iwamoto 2008 25mg PO (Figure 2) Safety-Tolerability-PK study-Weibull (lactose formulation)-Dissolution shape","Thalf",-0.377608283501881
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Lipophilicity","FractionAucLastToInf",-0.617249437393218
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Specific intestinal permeability (transcellular)","FractionAucLastToInf",-0.279415970829422
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A9-Kassahun 2007-In vitro Vmax for liver microsomes","FractionAucLastToInf",-0.102568780402432
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A1-Kassahun 2007-In vitro Vmax for liver microsomes","FractionAucLastToInf",-0.0331950662803968
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Iwamoto 2008 25mg PO (Figure 2) Safety-Tolerability-PK study-Weibull (lactose formulation)-Dissolution shape","FractionAucLastToInf",-0.732663069444162
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Lipophilicity","CL",0.400579556599509
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Specific intestinal permeability (transcellular)","CL",-0.127517098611095
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A9-Kassahun 2007-In vitro Vmax for liver microsomes","CL",0.254377023436418
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A1-Kassahun 2007-In vitro Vmax for liver microsomes","CL",0.456012488595366
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Iwamoto 2008 25mg PO (Figure 2) Safety-Tolerability-PK study-Weibull (lactose formulation)-Dissolution shape","CL",-0.60305619169459
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Lipophilicity","Vss",0.153669021992301
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Specific intestinal permeability (transcellular)","Vss",-0.290468491200132
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A9-Kassahun 2007-In vitro Vmax for liver microsomes","Vss",0.149345473524194
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A1-Kassahun 2007-In vitro Vmax for liver microsomes","Vss",0.362934392743024
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Iwamoto 2008 25mg PO (Figure 2) Safety-Tolerability-PK study-Weibull (lactose formulation)-Dissolution shape","Vss",-0.901565401746129
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Lipophilicity","Vd",0.0409241607490301
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Specific intestinal permeability (transcellular)","Vd",-0.136334332191175
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A9-Kassahun 2007-In vitro Vmax for liver microsomes","Vd",0.361991820671905
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A1-Kassahun 2007-In vitro Vmax for liver microsomes","Vd",0.631702224384526
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Iwamoto 2008 25mg PO (Figure 2) Safety-Tolerability-PK study-Weibull (lactose formulation)-Dissolution shape","Vd",-0.981537659252479
